LM
VYGR icon

Luminus Management’s Voyager Therapeutics VYGR Stock Holding History

Luminus Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-125,000
Closed -$2.35M – 183
2018
Q1 		$2.35M Buy
+125,000
New +$2.7M 0.05% 111

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Luminus Management's VYGR Position: Q2 2018 in Review

Luminus Management sold out of Voyager Therapeutics (VYGR) in Q2 2018, closing a stake of 125,000 shares — an estimated $2.35M sold.

Luminus Management first reported a position in VYGR in Q1 2018 and held it in 1 quarter. The position peaked at $2.35M in Q1 2018. 125 funds tracked by Wall St. Rank hold VYGR as of Q2 2018.

  • Luminus Management reported no remaining Voyager Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Luminus Management sold 125,000 Voyager Therapeutics shares in Q2 2018, an estimated $2.35M.
  • Luminus Management first reported a position in Voyager Therapeutics in Q1 2018 and held it in 1 quarter.
  • Luminus Management's Voyager Therapeutics position peaked at $2.35M in Q1 2018.
  • 125 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2018.

Based on Luminus Management's 13F filing for Q2 2018, filed 14 Aug 2018.